These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34862805)

  • 1. Gaining access to treatment; life at the far side of atopic eczema.
    Dolan M; Blake C; Cosgrave N; McMahon D; Greenwood M; Tobin AM
    Clin Exp Dermatol; 2022 Mar; 47(3):624-625. PubMed ID: 34862805
    [No Abstract]   [Full Text] [Related]  

  • 2. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 3. A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab.
    D'Adamio S; Massaro A; Biocca S; Bianchi L; Talamonti M; Galluzzo M
    Clin Exp Dermatol; 2020 Aug; 45(6):809-810. PubMed ID: 32472943
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe Adult Atopic Dermatitis: Clinical Challenges.
    Russo F; Flori ML; Gola M; Milanesi N
    Dermatitis; 2020; 31(4):e48-e49. PubMed ID: 32209869
    [No Abstract]   [Full Text] [Related]  

  • 5. Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Brodalumab.
    Gambardella A; Licata G; De Rosa A; Pagliuca F; Calabrese G; Alfano R; Argenziano G
    Dermatitis; 2021 Oct; 32(1S):e86-e88. PubMed ID: 33208631
    [No Abstract]   [Full Text] [Related]  

  • 6. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
    Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract]   [Full Text] [Related]  

  • 7. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
    Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
    J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis.
    Fowler E; Rosen J; Lev-Tov H; Yosipovitch G
    Acta Derm Venereol; 2019 Sep; 99(10):899-900. PubMed ID: 31037315
    [No Abstract]   [Full Text] [Related]  

  • 9. Alopecia Universalis and Atopic Dermatitis Improvement with Dupilumab: Demonstration of a Shared Pathophysiology and Clinical Efficacy.
    Dobkin H; Mullen R; Zirwas M
    Skinmed; 2019; 17(2):139-140. PubMed ID: 31145072
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and Efficacy of Dupilumab in an Atopic Adolescent With Primary Immune Deficiency.
    Tanner JF; Knutsen AP; Siegfried E
    Dermatitis; 2021 Oct; 32(1S):e91-e92. PubMed ID: 34677168
    [No Abstract]   [Full Text] [Related]  

  • 11. In the management of mild to moderate atopic dermatitis in adults.
    Recchia M
    J Drugs Dermatol; 2007 Mar; 6(3):252; author reply 252. PubMed ID: 17373186
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab for the treatment of atopic dermatitis.
    Fernández-Antón Martínez MC; Leis-Dosil V; Alfageme-Roldán F; Paravisini A; Sánchez-Ramón S; Suárez Fernández R
    Actas Dermosifiliogr; 2012 Sep; 103(7):624-8. PubMed ID: 22056257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
    Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.
    Drucker AM; Ellis AG; Bohdanowicz M; Mashayekhi S; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Küster D; Siegels D; Schmitt J; Flohr C
    JAMA Dermatol; 2020 Jun; 156(6):659-667. PubMed ID: 32320001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
    Salava A; Perälä M; Juppo M; Pelkonen AS; Mäkelä MJ; Remitz A
    Eur J Dermatol; 2021 Dec; 31(6):791-797. PubMed ID: 34935622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Burden of Atopic Dermatitis.
    Sibbald C; Drucker AM
    Dermatol Clin; 2017 Jul; 35(3):303-316. PubMed ID: 28577800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis.
    Fukuda K; Ishida W; Kishimoto T; Fukushima A
    Allergol Int; 2019 Jul; 68(3):383-384. PubMed ID: 30718036
    [No Abstract]   [Full Text] [Related]  

  • 20. Dupilumab improves both histaminergic and touch-evoked itch sensitization (hyperknesis) in atopic dermatitis: a pilot study.
    Hashimoto T; Okuno S; Okuzawa M; Satoh T
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):e911-e912. PubMed ID: 35735991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.